other:Article Title: Decreased Mrpl42 expression exacerbates myocardial ischemia and reperfusion injury by inhibiting mitochondrial translation.
Article Snippet: Primary antibodies against the following proteins were used: β-actin (ABclonal Technology Co., Ltd., China, AC004), HSP90 (Cell Signaling Technology, #4874S), Mrpl42 (ABclonal Technology Co., Ltd., China, A12811), cleavedcaspase 3 (Cell Signaling Technology, #9664), MT-ND1 (ABclonal Technology Co., Ltd., China, A18316), MT-ND2 (ABclonal Technology Co., Ltd., China, A17968), MT-ND3 (ABclonal Technology Co., Ltd., China, A17969), MT-ND4 (ABclonal Technology Co., Ltd., China, A9941), MT-ND5 (ABclonal Technology Co., Ltd., China, A17972), MTND6 (ABclonal Technology Co., Ltd., China, A17991), MT-COX1 (ABclonal Technology Co., Ltd., China, A17889), MT-COX2 (ABclonal Technology Co., Ltd., China, A17965), MT-COX3 (ABclonal Technology Co., Ltd., China, A17891), MT-ATP6 (ABclonal Technology Co., Ltd., China, A17960), MT-ATP8 (ABclonal Technology Co., Ltd., China, A17890), VDAC1 (ABclonal Technology Co., Ltd., China, A19707), Nrf2 (ABclonal Technology Co., Ltd., China, A1244), puromycin (ABclonal Technology Co., Ltd., China, A21205), Drp1 (ABclonal Technology Co., Ltd., China, A21968), Mfn1 (ABclonal Technology Co., Ltd., China, A21293), Mfn2 (ABclonal Technology Co., Ltd., China, A19678), Opa1 (ABclonal Technology Co., Ltd., China, A9833), p-Drp1 (S616) (Cell Signaling Technology, Inc. #3455) and p-Drp1 (S637) (Abcam Limited.
|